Physician profile
Sean Michael Warsch
NPI 1750608246
$36,979.62
in general payments reported to CMS, 2019-2025
62 companies · $4,876 in 2025
The $4,876 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.34 · 2020: $88.22 · 2021: $4,830 · 2022: $13K · 2023: $9,192 · 2024: $4,688 · 2025: $4,876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,478 · Food and Beverage: $6,158 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,297 · Travel and Lodging: $803 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,477.50 |
| Food and Beverage | $6,157.60 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,297.00 |
| Travel and Lodging | $802.93 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $16,450.44 | 2021-2024 | Libtayo |
| Genzyme Corporation | $4,831.38 | 2020-2023 | |
| Springworks Therapeutics, INC. | $1,807.61 | 2024-2025 | Ogsiveo |
| Karyopharm Therapeutics INC. | $1,707.86 | 2024-2025 | Xpovio |
| Beigene USA, INC. | $1,593.09 | 2020-2025 | Tevimbra, Brukinsa |
| Cti Biopharma Corp. | $1,437.50 | 2022 | |
| Caris Mpi, INC. | $1,167.48 | 2025 | Mi Cancer Seek |
| Daiichi Sankyo INC. | $1,040.63 | 2022-2025 | Enhertu, Datroway |
| Novartis Pharmaceuticals Corporation | $957.64 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $576.37 | 2020-2025 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $441.27 | 2021-2025 | Opdivo, Opdualag, Krazati |
| Celgene Corporation | $409.86 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Janssen Biotech, INC. | $387.58 | 2021-2025 | Tecvayli, Darzalex, Talvey |
| Pfizer INC. | $316.56 | 2021-2025 | |
| Astellas Pharma US INC | $215.22 | 2021-2025 | Padcev, Vyloy, Xospata |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $199.95 | 2021-2023 | Vectibix, Xgeva, Nplate |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.83 | 2021-2025 | Gilotrif |
| Genentech USA, INC. | $191.68 | 2022-2025 | Venclexta |
| Astrazeneca Pharmaceuticals Lp | $190.69 | 2021-2025 | Lynparza, Tagrisso, Imfinzi |
| Takeda Pharmaceuticals U.S.A., INC. | $188.64 | 2021-2024 | Ninlaro, Alunbrig, Iclusig |
| Glaxosmithkline, LLC. | $183.09 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Eisai INC. | $163.39 | 2022-2024 | |
| Stemline Therapeutics INC. | $152.14 | 2023 | Orserdu |
| Seagen INC. | $137.80 | 2020-2023 | Adcetris |
| Gilead Sciences, INC. | $133.87 | 2021-2025 | Trodelvy |
| Array Biopharma INC | $127.10 | 2023-2025 | Mektovi, Braftovi, Lorbrena |
| Alexion Pharmaceuticals, INC. | $123.78 | 2022-2024 | Ultomiris |
| Janssen Pharmaceuticals, INC | $116.30 | 2023-2024 | Xarelto |
| Mirati Therapeutics, INC. | $113.64 | 2023 | Krazati |
| Lilly USA, LLC | $94.71 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Puma Biotechnology, INC. | $81.42 | 2021-2025 | |
| Abbvie INC. | $80.82 | 2021-2025 | |
| Sobi, INC | $80.02 | 2024-2025 | |
| Deciphera Pharmaceuticals INC. | $71.59 | 2024-2025 | Qinlock, Romvimza |
| Aveo Pharmaceuticals, INC. | $67.36 | 2022-2025 | |
| Adaptive Biotechnologies Corporation | $66.49 | 2024-2025 | Clonoseq |
| G1 Therapeutics, INC. | $63.73 | 2022-2023 | Cosela |
| Servier Pharmaceuticals LLC | $62.80 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $57.70 | 2023-2025 | Zepzelca |
| Tersera Therapeutics LLC | $56.98 | 2022-2025 | Xermelo |
| Tactile Systems Technology INC | $53.14 | 2021-2022 | |
| Kyowa Kirin, INC. | $52.41 | 2021-2024 | Poteligeo |
| Beone Medicines USA, INC. | $49.79 | 2025 | Tevimbra |
| Agios Pharmaceuticals, INC. | $49.19 | 2024-2025 | Pyrukynd |
| Pharmaessentia USA Corporation | $46.22 | 2023-2024 | Besremi |
| Morphosys, US INC. | $39.82 | 2022-2023 | Monjuvi |
| Incyte Corporation | $37.07 | 2021-2025 | Jakafi |
| Pharmacosmos Therapeutics INC. | $32.87 | 2024 | Cosela |
| Taiho Oncology, INC. | $26.47 | 2025 | |
| Foundation Medicine, INC. | $25.30 | 2023 | |
| Sanofi-Aventis U.S. LLC | $24.84 | 2021 | |
| Rigel Pharmaceuticals, INC. | $22.05 | 2025 | Tavalisse |
| Spectrum Pharmaceuticals INC. | $20.83 | 2024 | Rolvedon |
| Tempus Ai, INC | $20.34 | 2025 | Xt Cdx |
| Syndax Pharmaceuticals, INC. | $18.92 | 2025 | |
| Acrotech Biopharma INC. | $18.89 | 2022 | |
| Medtronic, INC. | $18.19 | 2022 | |
| Ge Healthcare | $18.18 | 2023 | |
| Apellis Pharmaceuticals, INC. | $15.87 | 2023 | Empaveli |
| Myriad Genetic Laboratories, INC. | $15.69 | 2024 | Myrisk |
| Bayer Healthcare Pharmaceuticals INC. | $14.54 | 2022 | |
| Adc Therapeutics America, INC. | $12.99 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Warsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.